Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison

European Neurology

Volumn 47, Issue 2, 2002, Pages 99-107

  Diener, Hans Christoph ^a   Jansen, Jan Peter ^b   Reches, Avinoan ^c   Pascual, Julio ^d   Pitei, Daniela ^e   Steiner, Timothy J ^f  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Schwerpunktpraxis Schmerztherapie   (Germany)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cafergot; Efficacy; Eletriptan; Headache; Migraine; Safety

Indexed keywords

CAFERGOT; ELETRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ADOLESCENT; ADULT; AGED; CAFFEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ERGOTAMINE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PYRROLIDINES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0036179286     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047960     Document Type: Article

References (22)

1. Epidemiology of migraine and tension-type headache
2. Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemographic factors
3. Overview of diagnosis and treatment of migraine
4. Burden of migraine: Societal costs and therapeutic opportunities
5. A review of current treatments for migraine
6. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine
7. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine
8. The pharmacology of ergotamine and dihydroergotamine
9. Ergotamine in the acute treatment of migraine: A review and European consensus
10. Coronary side-effect potential of current and prospective antimigraine drugs
11. Intramuscular ergotamine: Plasma levels and dynamic activity
12. Effect of caffeine on intestinal absorption of ergotamine in man
13. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective '5-HT1D-like' receptor partial agonist
14. The safety, tolerability and pharmacokinetics of oral eletriptan (UK-116,044) a potent and selective '5-HT1D-like' receptor agonist
15. Single dose pharmacokinetics of sumatriptan in healthy volunteers
16. Eletriptan in acute migraine. A double-blind, placebo-controlled comparison to sumatriptan
17. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
18. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the treatment of acute migraine
19. An improved approximate formula for calculating sample size for comparing two binomial distributions
20. Comparisons between a new drug and active and placebo controls in an efficacy clinical trial
21. Efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine